[A case of liver cirrhosis with cyanosis (author's transl)].

H. Inoue,S. Yoneda,Y. Yazaki,A. Okubo,R. Mikami,K. Kosaka,T. Shiraishi

DOI: https://doi.org/10.11389/JJRS1963.15.722

1977-10-25

Abstract:

What problem does this paper attempt to address?

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

Donglin Xia,Hong He,Ying Wang,Kaiyu Wang,Huaqin Zuo,Haiying Gu,Peipei Xu,Yong Hu

DOI: https://doi.org/10.1016/j.actbio.2018.01.029

IF: 10.633

2018-01-01

Acta Biomaterialia

Abstract:Insulin (INS) delivery system that can mimic normal insulin secretion to maintain the blood glucose level (BGL) in the normal range is an ideal treatment for diabetes. However, most of the existing closed-loop INS delivery systems respond slowly to the changes in BGL, resulting in a time lag between the abnormal BGL and the release of INS, which is not suitable for practical application. In this study, glucose oxidase (GOx)-modified erythrocytes are used as INS carriers (GOx-INS-ER) that can rapidly self-regulate the release of INS upon the changes in BGL. In this system, glucose can be broken down into gluconic acid and hydrogen peroxide by GOx-INS-ER, and the latter will rupture the erythrocyte membrane to release INS within minutes. A pulsatile release of INS can be achieved upon the changes in the glucose concentration. This GOx-INS-ER enables diabetic rats to overcome hyperglycemia within 1 h, and a single injection of this GOx-INS-ER into the STZ-induced diabetic rats can maintain the BGL in the normal range up to 9 days. Statement of Significance Diabetes mellitus has been a major public health threatener with global prevalence. Although, glucose responsive carriers that can release insulin (INS) in a closed loop have been explored greatly in recent years, their sluggish glucose-responsive property and low INS-loading content greatly restrict their practical application [ACS Nano, 2013, 7, 4194]. In this work, we reported INS-loaded erythrocytes featuring ultrafast glucose-responsive property and high INS loading content, which could release INS in a closed loop. These GOX-INS-ERs could respond to the changes in glucose level within several minutes and self-regulate the release of INS for a long time. Single injection of GOX-INS-ER can overcome hyperglycemia in diabetic mice within 1 h and maintain the baseline level of glucose up to 9 days. We think our method may provide a robust way to potentiate diabetes treatment. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Antidiabetic Close Loop Based on Wearable DNA-Hydrogel Glucometer and Implantable Optogenetic Cells

Tiantian Man,Guiling Yu,Fulin Zhu,Yaqi Huang,Yueyu Wang,Yan Su,Shengyuan Deng,Hao Pei,Li Li,Haifeng Ye,Ying Wan

DOI: https://doi.org/10.1021/jacsau.4c00033

IF: 8

2024-04-06

JACS Au

Abstract:Diabetes mellitus and its associated secondary complications have become a pressing global healthcare issue. The current integrated theranostic plan involves a glucometer-tandem pump. However, external condition-responsive insulin delivery systems utilizing rigid glucose sensors pose challenges in on-demand, long-term insulin administration. To overcome these challenges, we present a novel model of antidiabetic management based on printable metallo-nucleotide hydrogels and optogenetic engineering. The conductive hydrogels were self-assembled by bioorthogonal chemistry using oligonucleotides, carbon nanotubes, and glucose oxidase, enabling continuous glucose monitoring in a broad range (0.5-40 mM). The optogenetically engineered cells were enabled glucose regulation in type I diabetic mice via a far-red light-induced transgenic expression of insulin with a month-long avidity. Combining with a microchip-integrated microneedle patch, a prototyped close-loop system was constructed. The glucose levels detected by the sensor were received and converted by a wireless controller to modulate far-infrared light, thereby achieving on-demand insulin expression for several weeks. This study sheds new light on developing next-generation diagnostic and therapy systems for personalized and digitalized precision medicine.
Hydrophobicity Regulation of Energy Acceptors Confined in Mesoporous Silica Enabled Reversible Activation of Optogenetics for Closed-Loop Glycemic Control

Qi Lu,Zihe Wang,Shumin Bai,Ying Wang,Cheng Liao,Yaru Sun,Yi Zhang,Wei Li,Qingsong Mei

DOI: https://doi.org/10.1021/jacs.2c13762

2023-03-15

Abstract:Optogenetics-based synthetic biology holds great promise as a cell-based therapy strategy for many clinical incurable diseases; however, precise control over genetic expression strength and timing through disease state-related closed-loop regulation remains a challenge due to the lack of reversible probes to indicate real-time metabolite fluctuations. Here, based on a novel mechanism of analyte-induced hydrophobicity regulation of energy acceptors confined in mesoporous silica, we developed a smart hydrogel platform comprising glucose reversible responsive upconversion nanoprobes and optogenetic engineered cells, in which the upconverted blue light strength was adaptively tuned through blood glucose levels to control optogenetic expressions for insulin secretion. The intelligent hydrogel system enabled convenient maintenance of glycemic homeostasis through simple near-infrared illuminations without any additional glucose concentration monitoring, which efficiently avoided genetic overexpression-induced hypoglycemia. This proof-of-concept strategy efficiently combines diagnostics with optogenetics-based synthetic biology for mellitus therapy, opening up a new avenue for nano-optogenetics.
Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

Guiling Yu,Mingliang Zhang,Ling Gao,Yang Zhou,Longliang Qiao,Jianli Yin,Yiwen Wang,Jian Zhou,Haifeng Ye

DOI: https://doi.org/10.1016/j.ymthe.2021.09.004

IF: 12.91

2022-01-01

Molecular Therapy

Abstract:Diabetes affects almost half a billion people, and all individuals with type 1 diabetes and a large portion of individuals with type 2 diabetes rely on self-administration of the peptide hormone insulin to achieve glucose control. However, this treatment modality has cumbersome storage and equipment requirements, and is susceptible to fatal user error. Here, reasoning that a cell-based therapy could be coupled to an external induction circuit for blood glucose control, as a proof-of-concept we developed far-red light (FRL) activated human islet-like designer (FAID) cells and demonstrated how FAID cell implants achieved safe and sustained glucose control in diabetic model mice. Specifically, by introducing a FRL-triggered optogenetic device into human mesenchymal stem cells (hMSCs), which we encapsulated in poly-(L-lysine)-alginate and implanted subcutaneously under the dorsum of type 1 diabetic (T1D) model mice, we achieved FRL-illumination-inducible secretion of insulin that yielded improvements in glucose tolerance and sustained blood glucose control over traditional insulin glargine treatment. Moreover, the FAID cell implants attenuated both oxidative stress and development of multiple diabetes-related complications in kidneys. This optogenetic-controlled "living cell factory" platform could be harnessed to develop multiple synthetic designer therapeutic cells to achieve long-term yet precisely controllable drug delivery.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Tether-free Optogenetic Control of Insulin Secretion Using an Upconversion Nanoparticle-Doped Hydrogel Platform.

Akshaya Bansal,Jing Zhang,Qi Lu,Qingsong Mei,Yong Zhang

DOI: https://doi.org/10.1039/d2bm01890j

2023-01-01

Biomaterials Science

Abstract:Glucagon-like peptide-1 (GLP-1), as a molecular therapeutic, induces glucose-dependent stimulation of insulin secretion, which has drawn significant attention in treating type II diabetes. However, it always suffers from hurdles such as short half-lives or instability. Thus, producing such therapeutics endogenously, as and when needed, is beneficial. Optogenetics-based production of GLP-1 offers an attractive alternative, wherein, the cell lines such as HEK293T can be genetically modified to bring the expression of the gene of interest under visible light control. However, the need for blue light for activation necessitates the implantation of invasive optical fibers owing to high tissue scattering and low depth of penetration through biological tissue at this wavelength. Here, we overcome this problem by proposing an upconversion nanoparticle (UCNP)-based system. HEK293T cells, rewired to produce GLP-1 under blue light illumination, were co-encapsulated with UCNPs in a hydrogel. The UCNPs act as near-infrared (NIR) to blue light nano-transducers, allowing deep penetration toward implementing a tether-free optogenetic gene expression platform. This platform is particularly powerful for thick gel implants (>3 mm) that cannot be illuminated throughout using a blue light source. Moreover, the GLP-1 produced in this platform was sufficient to increase insulin secretion in rat insulinoma cells, providing a powerful and controllable therapeutic tool for diabetes.
A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice

Ting Li,Xianjun Chen,Yajie Qian,Jiawei Shao,Xie Li,Shuning Liu,Linyong Zhu,Yuzheng Zhao,Haifeng Ye,Yi Yang

DOI: https://doi.org/10.1038/s41467-021-20913-1

2021-01-27

Abstract:Pulsing cellular dynamics in genetic circuits have been shown to provide critical capabilities to cells in stress response, signaling and development. Despite the fascinating discoveries made in the past few years, the mechanisms and functional capabilities of most pulsing systems remain unclear, and one of the critical challenges is the lack of a technology that allows pulsatile regulation of transgene expression both in vitro and in vivo. Here, we describe the development of a synthetic BRET-based transgene expression (LuminON) system based on a luminescent transcription factor, termed luminGAVPO, by fusing NanoLuc luciferase to the light-switchable transcription factor GAVPO. luminGAVPO allows pulsatile and quantitative activation of transgene expression via both chemogenetic and optogenetic approaches in mammalian cells and mice. Both the pulse amplitude and duration of transgene expression are highly tunable via adjustment of the amount of furimazine. We further demonstrated LuminON-mediated blood-glucose homeostasis in type 1 diabetic mice. We believe that the BRET-based LuminON system with the pulsatile dynamics of transgene expression provides a highly sensitive tool for precise manipulation in biological systems that has strong potential for application in diverse basic biological studies and gene- and cell-based precision therapies in the future.
Optogenetic therapeutic strategies for diabetes mellitus

Xin Deng,Dandan Peng,Yuanfa Yao,Ke Huang,Jinling Wang,Zhihao Ma,Junfen Fu,Yingke Xu

DOI: https://doi.org/10.1111/1753-0407.13557

IF: 4.53

2024-05-17

Journal of Diabetes

Abstract:Highlights Optogenetics has become a new evolving therapeutic approach for diabetes. Synthetic cells with light‐responsive modules for insulin/glucagon‐like peptide‐1 production have been developed to treat diabetes. Insulin‐responsive tissues are targets of optogenetics, which works to lower blood glucose and alleviate insulin resistance. The latest development of optogenetics in diabetes treatment and the remaining challenges are summarized. Diabetes mellitus (DM) is a common chronic disease affecting humans globally. It is characterized by abnormally elevated blood glucose levels due to the failure of insulin production or reduction of insulin sensitivity and functionality. Insulin and glucagon‐like peptide (GLP)‐1 replenishment or improvement of insulin resistance are the two major strategies to treat diabetes. Recently, optogenetics that uses genetically encoded light‐sensitive proteins to precisely control cell functions has been regarded as a novel therapeutic strategy for diabetes. Here, we summarize the latest development of optogenetics and its integration with synthetic biology approaches to produce light‐responsive cells for insulin/GLP‐1 production, amelioration of insulin resistance and neuromodulation of insulin secretion. In addition, we introduce the development of cell encapsulation and delivery methods and smart bioelectronic devices for the in vivo application of optogenetics‐based cell therapy in diabetes. The remaining challenges for optogenetics‐based cell therapy in the clinical translational study are also discussed.

endocrinology & metabolism
A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice

Chi-Yu Li,Ting Wu,Xing-Jun Zhao,Cheng-Ping Yu,Zi-Xue Wang,Xiao-Fang Zhou,Shan-Ni Li,Jia-Da Li

DOI: https://doi.org/10.3389/fbioe.2023.1052607

IF: 5.7

2023-02-11

Frontiers in Bioengineering and Biotechnology

Abstract:Exogenous insulin therapy is the mainstay treatment for Type-1 diabetes (T1D) caused by insulin deficiency. A fine-tuned insulin supply system is important to maintain the glucose homeostasis. In this study, we present a designed cell system that produces insulin under an AND gate control, which is triggered only in the presence of both high glucose and blue light illumination. The glucose-sensitive GIP promoter induces the expression of GI-Gal4 protein, which forms a complex with LOV-VP16 in the presence of blue light. The GI-Gal4:LOV-VP16 complex then promotes the expression of UAS-promoter-driven insulin. We transfected these components into HEK293T cells, and demonstrated the insulin was secreted under the AND gate control. Furthermore, we showed the capacity of the engineered cells to improve the blood glucose homeostasis through implantation subcutaneously into Type-1 diabetes mice.

multidisciplinary sciences
Self-Powered Intracellular Drug Delivery by a Biomechanical Energy-Driven Triboelectric Nanogenerator

Zhirong Liu,Jinhui Nie,Bin Miao,Jiadong Li,Yuanbo Cui,Shu Wang,Xiaodi Zhang,Gengrui Zhao,Yongbo Deng,Yihui Wu,Zhou Li,Linlin Li,Zhong Lin Wang

DOI: https://doi.org/10.1002/adma.201807795

IF: 29.4

2019-01-01

Advanced Materials

Abstract:Nondestructive, high-efficiency, and on-demand intracellular drug/biomacromolecule delivery for therapeutic purposes remains a great challenge. Herein, a biomechanical-energy-powered triboelectric nanogenerator (TENG)-driven electroporation system is developed for intracellular drug delivery with high efficiency and minimal cell damage in vitro and in vivo. In the integrated system, a self-powered TENG as a stable voltage pulse source triggers the increase of plasma membrane potential and membrane permeability. Cooperatively, the silicon nanoneedle-array electrode minimizes cellular damage during electroporation via enhancing the localized electrical field at the nanoneedle-cell interface and also decreases plasma membrane fluidity for the enhancement of molecular influx. The integrated system achieves efficient delivery of exogenous materials (small molecules, macromolecules, and siRNA) into different types of cells, including hard-to-transfect primary cells, with delivery efficiency up to 90% and cell viability over 94%. Through simple finger friction or hand slapping of the wearable TENGs, it successfully realizes a transdermal biomolecule delivery with an over threefold depth enhancement in mice. This integrated and self-powered system for active electroporation drug delivery shows great prospect for self-tuning drug delivery and wearable medicine.
Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes

Jinsong Shao,Lingzi Feng,Qingyu Zhao,Chao Chen,Jia Li,Qian Ma,Xiaohan Jiang,Ying Sun,Yanguang Yang,Haiying Gu,Yong Hu,Donglin Xia

DOI: https://doi.org/10.1016/j.jconrel.2021.11.021

IF: 11.467

2022-01-01

Journal of Controlled Release

Abstract:Exogenous insulin (INS) is critical for managing diabetes. However, owing to its short in vivo half-life, frequent injection of INS is un-avoidable, which is both painful and inconvenient, compromising the quality of life. Herein, we developed a laser-regulated INS release system (INS-ICG@ER hydrogel) that allowed an on-demand release of INS from the subcutaneous INS reservoir by remote laser control without the frequent injection of INS. The amino acid hydrogel functions as a hydrogel 3D scaffold material, which offers increased subcutaneous stability of drug loaded erythrocytes (ER). This INS-ICG@ER hydrogel would release INS due to the elevated content of reactive oxygen species (ROS), generated by ICG under laser irritation. Conversely, the ROS would be scavenged without the laser irradiation and stopped the release of INS from INS-ICG@ER hydrogel. Furthermore, the release of INS from INS-ICG@ER hydrogel could be regulated by laser irradiation. The INS-ICG@ER hydrogels could control the hyperglycemia within 2 h in diabetic mice and maintained their normal blood glucose level (BGL) for up to 6 days with laser irradiation 30 min prior to meals avoiding the frequent injection of free INS. This delivery system is an effective method that offers a spatiotemporally controlled release of INS to control the glucose level in vivo.
Light-Mediated Enhancement of Glucose-Stimulated Insulin Release of Optogenetically Engineered Human Pancreatic Beta-Cells

Zijing Chen,Demetrios M. Stoukides,Emmanuel S. Tzanakakis

DOI: https://doi.org/10.1021/acssynbio.3c00653

IF: 5.249

2024-02-22

ACS Synthetic Biology

Abstract:Enhancement of glucose-stimulated insulin secretion (GSIS) in exogenously delivered pancreatic β-cells is desirable, for example, to overcome the insulin resistance manifested in type 2 diabetes or to reduce the number of β-cells for supporting homeostasis of blood sugar in type 1 diabetes. Optogenetically engineered cells can potentiate their function with exposure to light. Given that cyclic adenosine monophosphate (cAMP) mediates GSIS, we surmised that optoamplification of GSIS is feasible in...

biochemical research methods
A Fully Integrated Closed‐Loop System Based on Mesoporous Microneedles‐Iontophoresis for Diabetes Treatment

Xiangling Li,Xinshuo Huang,Jingshan Mo,Hao Wang,Qiqi Huang,Cheng Yang,Tao Zhang,Hui‐Jiuan Chen,Tian Hang,Fanmao Liu,Lelun Jiang,Qianni Wu,Hongbo Li,Ning Hu,Xi Xie

DOI: https://doi.org/10.1002/advs.202100827

IF: 15.1

2021-06-03

Advanced Science

Abstract:<p>A closed-loop system that can mini-invasively track blood glucose and intelligently treat diabetes is in great demand for modern medicine, yet it remains challenging to realize. Microneedles technologies have recently emerged as powerful tools for transdermal applications with inherent painlessness and biosafety. In this work, for the first time to the authors' knowledge, a fully integrated wearable closed-loop system (IWCS) based on mini-invasive microneedle platform is developed for in situ diabetic sensing and treatment. The IWCS consists of three connected modules: 1) a mesoporous microneedle-reverse iontophoretic glucose sensor; 2) a flexible printed circuit board as integrated and control; and 3) a microneedle-iontophoretic insulin delivery component. As the key component, mesoporous microneedles enable the painless penetration of stratum corneum, implementing subcutaneous substance exchange. The coupling with iontophoresis significantly enhances glucose extraction and insulin delivery and enables electrical control. This IWCS is demonstrated to accurately monitor glucose fluctuations, and responsively deliver insulin to regulate hyperglycemia in diabetic rat model. The painless microneedles and wearable design endows this IWCS as a highly promising platform to improve the therapies of diabetic patients.</p>

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
A wearable, minimally-invasive, fully electrochemically-controlled feedback minisystem for diabetes management.

Yiqun Liu,Qi Yu,Le Ye,Li Yang,Yue Cui

DOI: https://doi.org/10.1039/d2lc00797e

IF: 7.517

2023-01-01

Lab on a Chip

Abstract:Diabetes is a chronic disease affecting 10% of the population globally, and can lead to serious damage in the heart, kidneys, eyes, blood vessels or nerves. Commercial artificial closed-loop feedback systems can significantly improve diabetes management and save lives. However, they are large and expensive for users. Here, we demonstrate for the first time a wearable, minimally-invasive, fully electrochemically-controlled feedback minisystem for diabetes management. Both the working principles of the sensor and pump in the feedback system are based on electrochemical reactions. The smart minisystem was constructed based on integrating the thermoplastic polyurethane hollow microneedles with an electrochemical biosensing device on its outer layer and an electrochemical micropump facing the inner layer of the microneedles. The sensing device was constructed based on sputtering thin metal films through a shadow mask and electroplating Prussian blue on the surface of the microneedles, followed by the immobilization of glucose oxidase on the working electrode. The electrochemical micropump was constructed by sputtering the interdigital electrodes, followed by sealing with a thin elastic film, which was further integrated with the inner channels of the microneedles. Both the sensor and the pump were electrically powered. being controlled by a printed circuit board, the biosensing device monitored the levels of interstitial glucose continuously to drive the electrochemical pump to deliver insulin intelligently, in order to control blood glucose within the normal range. The closed-loop feedback system was studied for its capability in maintaining the blood glucose levels of diabetic rats under various physiological conditions. The utility of the intelligent feedback system was successfully demonstrated on diabetic rats for controlling the blood glucose levels within the normal range. The minisystem is wearable, small, cost-effective, precise, stable and painless. It is anticipated that this approach opens a new paradigm for the development of closed-loop diabetes minisystems and may lead to a compelling future for diabetes management.
Glucose‐Operated Widget (GLOW) for Closed‐Loop Optogenetic Glycemic Control

Debasis Maity,Preetam Guha Ray,Martin Fussenegger

DOI: https://doi.org/10.1002/adma.202408537

IF: 29.4

2024-09-01

Advanced Materials

Abstract:This study introduces GLOWiβ, a closed‐loop insulin‐release system combining optogenetics and synthetic biology for diabetes management. Alginate microbeads encapsulating engineered iβ‐cells and a probe that emits glucose‐concentration‐dependent blue fluorescence enable precise control of insulin release. Successfully tested in a T1D mouse model, this approach has potential for personalized diabetes treatment. Closed‐loop control systems for precise control of therapeutic gene expression are promising candidates for personalized treatment of chronic ailments such as diabetes. Pancreatic iβ‐cells are engineered with blue‐light‐inducible melanopsin to drive rapid insulin release by vesicular secretion from intracellular stores. In this work, a glucose‐operated widget (GLOW) is designed as a component of a closed‐loop control system for diabetes treatment by employing a probe that emits blue fluorescence in a glucose‐concentration‐dependent manner as a real‐time glucose sensor to precisely control insulin release from these iβ‐cells. As proof‐of‐concept of the complete control system, the probe is encapsulated together with iβ‐cells in alginate‐poly‐(L‐lysine) hydrogel‐microbeads(400 μm in diameter and containing about 500 cells) called GLOWiβ (GLOW with iβ‐cells), are subcutaneously implanted into type‐1‐diabetic (T1D) mice. Illumination by UV‐A light at 390 nm results in glucose‐concentration‐dependent blue‐light emission from the probe at 445 nm that in turn induces glucose‐concentration‐dependent insulin release from the iβ‐cells in a fully reversible manner. Activation of the injected GLOWiβ at 390 nm for 15 min effectively restores normoglycemia within 60–120 min in a closed‐loop manner in these diabetic mice. The system is robust, as normoglycemia is well maintained by daily activation for at least 7 days.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Development of a Self-Powered Microneedle Based Wearable Electrochemical Sensor for Glucose Monitoring

Anindita Ganguly,Jun-Hsuan Chung,Kai Po Fan,Kuei-Lin Liu,Manish Kumar Sharma,Zong-Hong Lin

DOI: https://doi.org/10.1149/ma2023-01341891mtgabs

2023-08-28

ECS Meeting Abstracts

Abstract:Diabetes is increasingly being recognized as a worldwide public health concern owing to the affected rate of the patients in the past years. One of the major barriers to the disease control is the lack of sensitive and reliable point-of-care device that can provide quantitative diagnosis and monitoring. The wearable sensing technology has the potential of revolutionizing the precision medicine and personalized healthcare system. Within the emerging class of wearables, the microneedle-based sensors play a key role in combining the advantages of monitoring the analytes in interstitial fluid (ISF) and minimally invasive skin pricking. However, such devices require appropriate power sources to realize their full capacity, and the increasing power costs, global warming, and environmental pollution are certain aspects that needs to be pondered upon. Researches are dedicated on power generators with focus on wearable energy harvesters to address the issue of power supply. Thermoelectric generators (TEGs) have the ability to generate power by transforming thermal energy to electrical power output. Herein, we have developed a microneedle based enzymatic, electrochemical glucose sensing system powered by TEG utilizing the body heat. 1 mm stainless steel microneedles were sputtered with gold and platinum, and further coated with graphene paste, glucose oxidase, poly-hydroxyethyl methacrylate, and nafion. The fabricated device exhibited a good sensitivity, and a wide linear range. According to the World Health Organization (WHO), the normal glucose level in human body are between 4.0 mM to 5.6 mM, and our device has shown a concentration dependent output current signal from 4.0 mM to 24.0 mM. The device has also exhibited excellent detection results in real-sample (artificial ISF) in vitro study as well as in vivo analysis performed in 12 – 15 weeks SD rats. The device is completely self-powered where the TEG derives power from the temperature gradient between the body heat and the exposed environment. The novelty of this work lies in integrating the microneedle-based sensing device with the TEG as the power source. The results indicate a promising self-powered sensor with the renewable and sustainable source of power ensuring continuous operation.
Glucose-activated switch regulating insulin analogue secretion enables long-term precise glucose control in type 1 diabetes mice

Lifang Xie,Wanling Lu,Yanhan Zhang,Lu Deng,Ming Liu,Hong Gao,Chunguang Xie,Gang Wang

DOI: https://doi.org/10.2337/db22-0860

IF: 7.7

2023-03-15

Diabetes

Abstract:Genetic modification of non-β cells to produce insulin is a promising therapeutic strategy for type 1 diabetes, however, it is associated with issues including biosafety and precise regulation of insulin supply. In this study, a glucose-activated singlestrand insulin analogue (SIA) switch (GAIS) was constructed to achieve repeatable pulse activation of SIA secretion in response to hyperglycemia. In the GAIS system, the CAD-FCS-SIA fusion protein was encoded by the intramuscularly delivered plasmid and temporarily kept in the endoplasmic reticulum (ER) as it binds to the GRP78 protein, then upon hyperglycemia, SIA was released and secreted into the blood. In vitro and in vivo experiments systematically demonstrated the effects of the GAIS system, including glucose-activated and repeatable SIA secretion, long-term precise blood glucose control, recovered HbA1c level, improved glucose tolerance, and ameliorated oxidative stress. Additionally, this system offers sufficient biosafety as evidenced by the assays of immunological and inflammatory safety, ER stress, histological evaluation, etc. Compared with the viral delivery/expression system, the ex vivo implantation of engineered cells, and the exogenous inducer system, the GAIS system combined the advantages of biosafety, effectiveness, persistence, precision, and convenience, providing therapeutic potential for the treatment of type 1 diabetes. Article Highlights We undertake this study to establish a glucose-responsive SIA self-supply system in vivo. Whether ER can serve as a safe and temporary repository to store designed fusion proteins and release SIAs under hyperglycemia condition for efficient blood glucose regulation. Intramuscularly expressed plasmid-encoded CAD-FCS-SIA fusion protein can be temporarily stored in ER and SIA can be released under the stimulation of hyperglycemia, resulting in efficient and long-term regulation of blood glucose stable in T1D mice. GAIS system provides applicable potential for type 1 diabetes therapy integrating regulation and monitor of blood glucose level.

endocrinology & metabolism
Dual Activation of Calcium Channels Using Near-Infrared Responsive Conjugated Oligomer Nanoparticles for Precise Regulation of Blood Glucose Homeostasis

Ning Li,Chen Li,Boying Li,Chaoqun Li,Qi Zhao,Zhongming Huang,Yue Shu,Xiongwei Qu,Baiqi Wang,Shengliang Li,Chengfen Xing

DOI: https://doi.org/10.1021/acs.nanolett.3c03701

IF: 10.8

2023-11-10

Nano Letters

Abstract:The rarity of efficient tools with spatiotemporal resolution and biocompatibility capabilities remains a major challenge for further progress and application of signaling manipulation. Herein, biomimetic conjugated oligomeric nanoparticles (CM-CONs) were developed to precisely modulate blood glucose homeostasis via the two-pronged activation of calcium channels. Under near-infrared (NIR) laser irradiation, CM-CONs efficiently generate local heat and reactive oxygen species (ROS), thereby simultaneously activating thermosensitive transient receptor potential V1 (TRPV1) and ROS-sensitive transient receptor potential A1 (TRPA1) calcium channels in small intestinal endocrine cells. The activation of the channels mediates inward calcium flow and then promotes glucagon-like peptide (GLP-1) secretion. Both in vitro and in vivo studies indicate that CM-CONs effectively regulate glucose homeostasis in diabetic model mice upon NIR light irradiation. This work develops a two-pronged attack strategy for accurately controlling blood glucose homeostasis, holding great prospects in the treatment for diabetes.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Regulation of Blood Glucose Using Islets Encapsulated in a Melanin-Modified Immune-Shielding Hydrogel

Ling Huang,Jiajia Xiang,Yukai Cheng,Ling Xiao,Qingqing Wang,Yini Zhang,Tieling Xu,Qianrui Chen,Hongbo Xin,Xiaolei Wang

DOI: https://doi.org/10.1021/acsami.0c23010

2021-03-10

Abstract:Islet transplantation is currently a promising treatment for type 1 diabetes mellitus. However, the foreign body reaction and retrieval difficulty often lead to transplantation failure and hinder the clinical application. To address these two challenges, we propose a balanced charged sodium alginate–polyethyleneimine–melanin (SA–PEI–Melanin) threadlike hydrogel with immune shielding and retrievable properties. The attractiveness of this study lies in that the introduction of melanin can stimulate insulin secretion, especially under near-infrared (NIR) irradiation. After demonstrating a good immune-shielding effect, we performed an <i>in vivo</i> transplantation experiment. The results showed that the blood glucose level in the SA–PEI–Melanin group was stably controlled below the diabetic blood glucose criterion, and this blood glucose level could be further adjusted after NIR irradiation. In addition, the evaluation after retrieving the SA–PEI–Melanin hydrogel indicated that the islets still maintained a normal physiological function, further proving its excellent immunological protection. This study provides a new approach for the accurate regulation of blood glucose in patients with type 1 diabetes mellitus and contributes to developing a promising transplant system to reconcile real-time and precise light-defined insulin secretion regulation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c23010?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c23010</a>.Microscopic image of SA–PEI–Melanin threadlike hydrogel encapsulated with islets (Figure S1); particle size distribution of melanin nanoparticles (Figure S2); HE staining images of SA hydrogel and different ratios (SA/PEI/Melanin; 10:0.80:0.0005, 10:0.80:0.004, 10:0.80:0.009; v/v/w) of hydrogel samples removed 1 week after implantation (Figure S3); HE staining images of heart, liver, spleen, lung, kidney, and liver in different groups of mice, respectively (Figure S4A); comparison of neutrophil percentage in different groups of mice (Figure S4B); and comparison of white blood cell counts in different groups of mice (Figure S4C) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c23010/suppl_file/am0c23010_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology
A Wireless Closed Loop System for Optogenetic Peripheral Neuromodulation

Aaron D. Mickle,Sang Min Won,Kyung Nim Noh,Jangyeol Yoon,Kathleen W. Meacham,Yeguang Xue,Lisa A. McIlvried,Bryan A. Copits,Vijay K. Samineni,Kaitlyn E. Crawford,Do Hoon Kim,Paulome Srivastava,Bong Hoon Kim,Seunghwan Min,Young Shiuan,Yeojeong Yun,Maria A. Payne,Jianpeng Zhang,Hokyung Jang,Yuhang Li,H. Henry Lai,Yonggang Huang,Sung-Il Park,Robert W. Gereau IV,John A. Rogers

DOI: https://doi.org/10.1038/s41586-018-0823-6

IF: 64.8

2018-01-01

Nature

Abstract:The fast-growing field of bioelectronic medicine aims to develop engineered systems that can relieve clinical conditions by stimulating the peripheral nervous system1–5. This type of technology relies largely on electrical stimulation to provide neuromodulation of organ function or pain. One example is sacral nerve stimulation to treat overactive bladder, urinary incontinence and interstitial cystitis (also known as bladder pain syndrome)4,6,7. Conventional, continuous stimulation protocols, however, can cause discomfort and pain, particularly when treating symptoms that can be intermittent (for example, sudden urinary urgency)8. Direct physical coupling of electrodes to the nerve can lead to injury and inflammation9–11. Furthermore, typical therapeutic stimulators target large nerve bundles that innervate multiple structures, resulting in a lack of organ specificity. Here we introduce a miniaturized bio-optoelectronic implant that avoids these limitations by using (1) an optical stimulation interface that exploits microscale inorganic light-emitting diodes to activate opsins; (2) a soft, high-precision biophysical sensor system that allows continuous measurements of organ function; and (3) a control module and data analytics approach that enables coordinated, closed-loop operation of the system to eliminate pathological behaviours as they occur in real-time. In the example reported here, a soft strain gauge yields real-time information on bladder function in a rat model. Data algorithms identify pathological behaviour, and automated, closed-loop optogenetic neuromodulation of bladder sensory afferents normalizes bladder function. This all-optical scheme for neuromodulation offers chronic stability and the potential to stimulate specific cell types. A closed-loop implantable bioelectronic device that can modulate peripheral neuronal activity is used to improve bladder function in a rat model of cystitis.
Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules

Jin Di,Jicheng Yu,Qun Wang,Shanshan Yao,Dingjie Suo,Yanqi Ye,Matthew Pless,Yong Zhu,Yun Jing,Zhen Gu

DOI: https://doi.org/10.1007/s12274-017-1500-z

IF: 9.9

2017-03-06

Nano Research

Abstract:Diabetes is a serious public health problem affecting 422 million people worldwide. Traditional diabetes management often requires multiple daily insulin injections, associated with pain and inadequate glycemia control. Herein, we have developed an ultrasound-triggered insulin delivery system capable of pulsatile insulin release that can provide both long-term sustained and fast on-demand responses. In this system, insulin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocapsules are encapsulated within chitosan microgels. The encapsulated insulin in nanocapsules can passively diffuse from the nanoparticle but remain restricted within the microgel. Upon ultrasound treatment, the stored insulin in microgels can be rapidly released to regulate blood glucose levels. In a chemically-induced type 1 diabetic mouse model, we demonstrated that this system, when activated by 30 s ultrasound administration, could effectively achieve glycemic control for up to one week in a noninvasive, localized, and pulsatile manner.

materials science, multidisciplinary,chemistry, physical,physics, applied,nanoscience & nanotechnology

[A case of liver cirrhosis with cyanosis (author's transl)].

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

Antidiabetic Close Loop Based on Wearable DNA-Hydrogel Glucometer and Implantable Optogenetic Cells

Hydrophobicity Regulation of Energy Acceptors Confined in Mesoporous Silica Enabled Reversible Activation of Optogenetics for Closed-Loop Glycemic Control

Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

Tether-free Optogenetic Control of Insulin Secretion Using an Upconversion Nanoparticle-Doped Hydrogel Platform.

A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice

Optogenetic therapeutic strategies for diabetes mellitus

A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice

Self-Powered Intracellular Drug Delivery by a Biomechanical Energy-Driven Triboelectric Nanogenerator

Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes

Light-Mediated Enhancement of Glucose-Stimulated Insulin Release of Optogenetically Engineered Human Pancreatic Beta-Cells

A Fully Integrated Closed‐Loop System Based on Mesoporous Microneedles‐Iontophoresis for Diabetes Treatment

A wearable, minimally-invasive, fully electrochemically-controlled feedback minisystem for diabetes management.

Glucose‐Operated Widget (GLOW) for Closed‐Loop Optogenetic Glycemic Control

Development of a Self-Powered Microneedle Based Wearable Electrochemical Sensor for Glucose Monitoring

Glucose-activated switch regulating insulin analogue secretion enables long-term precise glucose control in type 1 diabetes mice

Dual Activation of Calcium Channels Using Near-Infrared Responsive Conjugated Oligomer Nanoparticles for Precise Regulation of Blood Glucose Homeostasis

Regulation of Blood Glucose Using Islets Encapsulated in a Melanin-Modified Immune-Shielding Hydrogel

A Wireless Closed Loop System for Optogenetic Peripheral Neuromodulation

Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules